secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACELYRIN, Inc. (—)
CIK:        0001962918
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001962918-24-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACELYRIN reports FY 2023 net loss of $381.6M; cash $721.3M; pipeline progress with izokibep and lonigutamab
--------------------------------------------------------------------------------

- Net loss $381.6M in 2023 vs $64.8M in 2022; R&D expenses $355.9M including $123.1M IPR&D from ValenzaBio acquisition.
- Cash, equivalents and marketable securities $721.3M expected to fund operations into 2026 through late-stage registrational studies.
- Positive Phase 1/2 data for lonigutamab (subcutaneous anti-IGF-1R) in thyroid eye disease with rapid proptosis improvements at 3 weeks.
- Phase 2b/3 trial of izokibep met primary endpoint ACR50 at 16 weeks with high statistical significance in psoriatic arthritis; HS Phase 3 topline data expected H2 2024.
- Appointed Agnes Lee as SVP IR and Corporate Communications; Lynn Tetrault joined Board in December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/0001962918-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000030/slrn-20240328.htm
  HTML page:      https://secwatch.observer/filing/0001962918-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer